Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.
Manige KonigMatthew C RiddleHelen M ColhounKelley R BranchCharles M AtissoMark C LakshmananReema ModySohini RahaHertzel C GersteinPublished in: Cardiovascular diabetology (2021)
Treatment-induced improvement in HbA1c and UACR, but not changes in weight, systolic blood pressure, or LDL cholesterol, appear to partly mediate the beneficial effects of dulaglutide on MACE outcomes. These observations suggest that the proven effects of dulaglutide on cardiovascular disease benefit are partially related to changes in glycemic control and albuminuria, with residual unexplained benefit. Clinicaltrials.gov; Trial registration number: NCT01394952. URL: https://clinicaltrials.gov/ct2/show/NCT01394952.
Keyphrases
- glycemic control
- type diabetes
- blood pressure
- cardiovascular disease
- blood glucose
- weight loss
- end stage renal disease
- heart failure
- ejection fraction
- newly diagnosed
- chronic kidney disease
- left ventricular
- clinical trial
- computed tomography
- prognostic factors
- insulin resistance
- randomized controlled trial
- low density lipoprotein
- magnetic resonance imaging
- heart rate
- coronary artery disease
- contrast enhanced
- positron emission tomography
- phase ii
- cardiovascular events
- adipose tissue
- endothelial cells
- risk assessment
- oxidative stress
- phase iii
- dual energy
- patient reported outcomes
- atrial fibrillation
- patient reported
- climate change